Artivion
AORT
About: Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
Employees: 1,600
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
11,200% more call options, than puts
Call options by funds: $678K | Put options by funds: $6K
26% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 23
25% more capital invested
Capital invested by funds: $1.04B [Q1] → $1.3B (+$258M) [Q2]
25% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 57
2% more funds holding
Funds holding: 184 [Q1] → 188 (+4) [Q2]
0.02% more ownership
Funds ownership: 97.67% [Q1] → 97.68% (+0.02%) [Q2]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
|
Needham
Mike Matson
|
$50
|
Buy
Maintained
|
22 Aug 2025 |
|
Ladenburg Thalmann
Jeff Cohen
|
$39
|
Neutral
Downgraded
|
13 Aug 2025 |
|
Canaccord Genuity
William Plovanic
|
$41
|
Buy
Maintained
|
8 Aug 2025 |
|
JMP Securities
Daniel Stauder
|
$42
|
Market Outperform
Maintained
|
8 Aug 2025 |
|
Stifel
Rick Wise
|
$40
|
Buy
Maintained
|
8 Aug 2025 |
Financial journalist opinion
Based on 3 articles about AORT published over the past 30 days
